Faculty & Research Interests

Faculty


Agnes Cha, Pharm.D., AAHIVP, BCACP
Associate Professor, Pharmacy Practice
Agnes.Cha@liu.edu
(718) 488-1000 / Ext-1724


Education

Pharm. D., University of Illinois at Chicago, Chicago, IL
Post Graduate Year-1 Pharmacy Residency, Veteran Affairs – New York Harbor Healthcare System, New York, NY
Post Graduate Year-2 Ambulatory Care Residency, The Brooklyn Hospital, Brooklyn, NY




Short Biography

Dr. Agnes Cha graduated summa cum laude from the University of Illinois College of Pharmacy in Chicago, IL. Dr. Cha moved to NYC to pursue her interest in HIV/AIDS and ambulatory care. She completed a Post Graduate Year-1 Pharmacy Practice Residency at the Veterans Affairs Hospital in New York, NY and a Post Graduate Year-2 Ambulatory Care Residency with a focus on HIV Primary Care at the Brooklyn Hospital Center. Dr. Cha has obtained certification as an HIV Pharmacist by the American Academy of HIV Medicine and is also a Board Certified Ambulatory Care Pharmacist. Dr. Cha is currently an Associate Professor of Pharmacy Practice at LIU College of Pharmacy and has been practicing as an HIV clinical pharmacist at a HIV Primary Care clinic affiliated with the Brooklyn Hospital Center. She has implemented an interdisciplinary practice model and promotes pharmacist involvement on the medical team. She has also initiated a pharmacist-run Hepatitis C clinic and manages co-infected patients. Her passion centers on caring for HIV positive patients, both treatment naïve and experienced, and their co-morbidities as pharmacotherapy management becomes more complex. Dr. Cha serves as a preceptor for the Brooklyn Hospital Center's pharmacy residency program, for PGY1, PGY2-ID, and PGY-2 ambcare residents where she is a primary investigator for several research projects and oversees the Antiretroviral Stewardship Program. Dr. Cha also serves as a Director-At-Large for the Royal Counties chapter of New York State Council of Health-Systems Pharmacists (NYSCHP). She is also a strong advocate for expanding student experiences in resource poor countries through the International Pharmacy Practice & Public Health elective rotation.


Research Synopsis

HIV/AIDS and Hepatitis C: Research centers on the management of patients with HIV and their comorbidities. Involved in evaluating the efficacy and safety of antivirals for HIV/Hepatitis C coinfection, evaluating interdisciplinary practice models and the impact of clinical pharmacists on patient care, reducing clinically significant drug-drug interactions with antiretrovirals, evaluating the reversibility of tenofovir related renal dysfunction, and applying cardiovascular risk assessment tools in HIV patients.

Current projects include assessing real-world experience with higher than recommended doses of lamivudine in varying degrees of renal impairment, and observing the clinical significance of dolutegravir and metformin co-administration.


Selected Publications

  • Del Bello D, Cha A*, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D, Odin J, Schiano TD, Fierer DS, Berkowitz L, Perumalswami PV, Dieterich DT, Branch AD. “Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV” Clin Infect Dis. 2016; Jun 15;62(12):1497-504. doi: 10.1093/cid/ciw119. Epub 2016 Mar 1.] Co-first author (*alternate corresponding author). http://www.ncbi.nlm.nih.gov/pubmed/26936665
  • Cha A, Besignano-Long AR, Rothberger N, Shah B. “Reversibility of renal dysfunction after discontinuation of tenofovir.” J Am Pharm Assoc. 2016; May-Jun; 56(3):280-3. [DOI: 10.1016/j.japh.2016.02.013]. http://www.ncbi.nlm.nih.gov/pubmed/27067552
  • Cha A, Elsamadisi P, Su CP, Phipps E, Birnbaum JM. “Prevention of perinatal transmission of zidovudine- and nevirapine- resistant HIV.” Am J Health Syst Pharm. 2016; Apr 1; 73(7):451-5. [DOI: 10.2146/ajhp150620.]. http://www.ncbi.nlm.nih.gov/pubmed/27001986
  • Elsamadisi P, Cha A, Kim E, Latif S. “Statin use with the ATP III guidelines compared to the 2013 ACC/AHA guidelines in HIV primary care patients” J Pharm Pract. 2015; Nov 18; Epub ahead of print. [DOI: 10.1177/0897190015611774]. http://www.ncbi.nlm.nih.gov/pubmed/26584848
  • Billedo J, Berkowitz L, Cha A*. “Evaluating the impact of a pharmacist-led antiretroviral stewardship program on reducing drug interactions in HIV-infected patients” J Int Assoc Provid AIDS Care. 2015; Aug 19; Epub ahead of print. [DOI: 10.1177/2325957415600700] *Corresponding author. http://www.ncbi.nlm.nih.gov/pubmed/26289342
  • Cope R, Berkowitz L, Arcebido R, Yeh JY, Trustman N, Cha A*. “Evaluating the effects on an interdisciplinary practice model with pharmacist collaboration on HIV patient co-morbidities” AIDS Patient Care STDS. 2015; Aug;29(8):445-53. [DOI: 10.1089/apc.2015.0018] *Corresponding author. http://www.ncbi.nlm.nih.gov/pubmed/26125093
  • Cha, Agnes. “Chapter 37: HIV/AIDS” Primary Care, 2nd Edition: An Interprofessional Perspective. Ed. Joanne K. Singleton. New York: Springer Publishing Company, 2015. 555-585. Print.
  • Cha A, Budovich A. “Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection” Pharmacy & Therapeutics. 2014; 39(5): 345-352. http://www.ncbi.nlm.nih.gov/pubmed/24883006
  • Bias TE, Venugopalan V, Berkowitz LB, Cha A. “Incidence of antiretroviral drug interactions during hospital course: The role of a pharmacist-led antiretroviral stewardship” J Pharm Technol. 2014; 30(2): 48-53. [DOI 10.1177/8755122513500919]
  • Vachirasudlekha B, Cha A, Berkowitz L, Shah B. “Interdisciplinary HIV care - Patient perceptions.” Int J Health Care Qual Assur. 2014; 27(5): 405-413. [DOI 10.1108/IJHCQA-01-2013-0007]. http://www.ncbi.nlm.nih.gov/pubmed/25087338
  • Cha A, Shaikh R, Williams S, Berkowitz L. “Rapid reduction of HIV viral load in late pregnancy with raltegravir: a case report.” J Int Assoc Provid AIDS Care. 2013; 12 (5): 312-4 [DOI 10.1177/2325957413488176]. http://www.ncbi.nlm.nih.gov/pubmed/23695227
  • Gatti D, Cha A. “Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection.” Am J Health-Syst Pharm. 2012; 69:2062-65 [DOI: 10.2146/ajhp120220]. http://www.ncbi.nlm.nih.gov/pubmed/23172264
  • Cha A. “Ask the HIV Specialist: Elevated (Liver) Concerns.” Positively Aware. May/June 2011; 41.
  • Berrios-Colon E, Cha A. The treatment and management of atrial fibrillation. US Pharmacist. 2010, 35(2):26-38.

CONTACT

LIU Pharmacy
John M. Pezzuto, A.B., Ph.D.
Dean